Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
Authors:
- Deniz BorcakDeniz Borcak
- Zuhal YesilbagZYZuhal Yesilbag
- Yusuf Emre OzdemirYOYusuf Emre Ozdemir
- Adile Sevde DemirADAdile Sevde Demir
- Esra Salim DogdasEDEsra Salim Dogdas
- Aysegul Inci SezenASAysegul Inci Sezen
- Esra Canbolat UnluEUEsra Canbolat Unlu
- Sevtap SenogluSSSevtap Senoglu
- Hayat Kumbasar KaraosmanogluHKHayat Kumbasar Karaosmanoglu
- Kadriye Kart YasarKYKadriye Kart Yasar
Open Access
- 18 November 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8164
Abstract
Background/Objectives: The accurate evaluation of the fibrosis stage is critical for improving chronic hepatitis B (CHB) management and patient outcomes. This study aimed to compare the diagnostic accuracy of non-invasive fibrosis markers with liver biopsy for detecting significant, advanced fibrosis and cirrhosis. We further investigated the diagnostic performance of non-invasive markers according to HBeAg status to provide further insight into their clinical utility across patient subgroups. Methods: This single-center retrospective study included 536 treatment-naive patients with CHB who underwent liver biopsy. Patients were categorized into four groups according to the fibrosis stage: “no significant fibrosis” (F0–F2), “significant fibrosis” (F3–F6), “advanced fibrosis” (F4–F6), and “cirrhosis” (F5–F6). AAR, AAPRI, APRI, API, FIB-4, GPR, and S–index were compared among these groups. Results: In total, 536 treatment-naïve patients were analyzed (63.2% male; mean age 44.8 ± 12.9 years), of whom 25.4% were HBeAg-positive. API, FIB 4, GPR, and S-Index showed good performance (area under the curve [AUC] ≥ 0.8–0.9) in defining advanced fibrosis (≥F4), AAPRI, AAR, API, and APRI showed good performance ([AUC] < 0.700) in defining cirrhosis. The analysis showed that GPR had the highest AUC for ≥F3 (0.719) and ≥F4 (0.838), while FIB 4 had the highest AUC for cirrhosis (0.865). Conclusions: These findings highlight the value of non-invasive markers as inexpensive and easily applicable methods for clinicians in assessing the stage of liver fibrosis. The integration of these scores into the routine monitoring of chronic hepatitis B patients is expected to expand, enhancing clinical decision-making and reducing the necessity for liver biopsies.Keywords
This publication has 37 references indexed in Scilit:
- EASL Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2025
- Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2025
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosisHepatology, 2024
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 updateJournal of Hepatology, 2021
- Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-AnalysisDigestive Diseases and Sciences, 2021
- A new combined predicting model using a non-invasive score for the assessment of liver fibrosis in patients presenting with chronic hepatitis B virus infectionMedecine Et Maladies Infectieuses, 2019
- Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 updateHepatology International, 2016
- Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C TrialClinical Gastroenterology and Hepatology, 2010
- Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virusJournal of Viral Hepatitis, 1997
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995